Loading
A phase 2 trial of Durvalumab, Bevacizumab in hepatocellular carcinoma, run by AstraZeneca, active and no longer recruiting.
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE is a phase 2 interventional study registered as NCT06040099 by AstraZeneca, with 58 participants enrolled, started 2024-02-13 and due to reach its primary completion in 2026-07-01. Interventions recorded: Durvalumab, Bevacizumab, Transarterial Radioembolization (TARE). Conditions listed: Hepatocellular Carcinoma (HCC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Durvalumab, Bevacizumab, Anti-angiogenic therapy, AstraZeneca.
Shares Durvalumab, Bevacizumab, Anti-angiogenic therapy, AstraZeneca.
Shares Durvalumab, Anti-angiogenic therapy, AstraZeneca, Hepatocellular carcinoma.
Shares Durvalumab, AstraZeneca, Hepatocellular carcinoma, Immune checkpoint inhibitors.
Shares Durvalumab, AstraZeneca, Hepatocellular carcinoma, Immune checkpoint inhibitors.
Shares Durvalumab, Bevacizumab, Anti-angiogenic therapy, AstraZeneca.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors.
Shares Durvalumab, Bevacizumab, AstraZeneca, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/